Chinese Science Bulletin

, Volume 54, Issue 3, pp 394–398 | Cite as

Endogenously generated amyloid β increases membrane fluidity in neural 2a cells

  • Ying Niu
  • BaiYang Sheng
  • Bo Song
  • LingLing Liu
  • XiuFang Zhang
  • NanMing Zhao
  • YanDao Gong
Articles/Biophysics
First Online:
Received:
Accepted:

Abstract

The effect of endogenously generated amyloid β on membrane fluidity was investigated in Neural 2a cells stably expressing Swedish mutant amyloid precursor protein (APPswe). Membrane fluidity was studied by fluorescence polarizability using 1,6-Diphenyl-1,3,5-Hexatriene (DPH) as the fluorescence probe. It was found that the membrane fluidity in APPswe cells was significantly higher than that in its wild type counterparts. Alleviating the effect of amyloid β either by γ secretase activity inhibition or by amyloid antibody treatment decreased membrane fluidity, which indicated an important role of amyloid β in increasing membrane fluidity. Treatment using amyloid β channel blocker, tromethamine and NA4 suggested that channel formed by amyloid β on the cell membrane is a way through which amyloid β takes its membrane fluidizing effect.

Keywords

membrane fluidity fluorescence polarizability Alzheimer’s disease amyloid β 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kang J, Lemaire H G, Unterbeck A, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987, 325(6106): 733–736CrossRefGoogle Scholar
  2. 2.
    Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet, 1992, 1(5): 345–347CrossRefGoogle Scholar
  3. 3.
    Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta- protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med, 1996, 2(8): 864–870CrossRefGoogle Scholar
  4. 4.
    Kremer J J, Pallitto M M, Sklansky D J, et al. Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry, 2000, 39(33): 10309–10318CrossRefGoogle Scholar
  5. 5.
    Mingeot-Leclercq M P, Lins L, Bensliman M, et al. Membrane destabilization induced by beta-amyloid peptide 29-42: Importance of the amino-terminus. Chem Phys Lipids, 2002, 120(1–2): 57–74CrossRefGoogle Scholar
  6. 6.
    Bokvist M, Lindstrom F, Watts A, et al. Two types of Alzheimer’s beta-amyloid (1-40) peptide membrane interactions: Aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol, 2004, 335(4): 1039–1049CrossRefGoogle Scholar
  7. 7.
    Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem, 2004, 279(45): 46363–46366CrossRefGoogle Scholar
  8. 8.
    Ciccotosto G D, Tew D, Curtain C C, et al. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem, 2008, 279(41): 42528–42534CrossRefGoogle Scholar
  9. 9.
    Tickler A K, Smith D G, Ciccotosto G D, et al. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem, 2005, 280(14): 13355–13363CrossRefGoogle Scholar
  10. 10.
    Demuro A, Mina E, Kayed R, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem, 2005, 280(17): 17294–17300CrossRefGoogle Scholar
  11. 11.
    Demeester N, Baier G, Enzinger C, et al. Apoptosis induced in neuronal cells by C-terminal amyloid beta-fragments is correlated with their aggregation properties in phospholipid membranes. Mol Membr Biol, 2000, 17(4): 219–228CrossRefGoogle Scholar
  12. 12.
    Muller W E, Koch S, Eckert A, et al. beta-Amyloid peptide decreases membrane fluidity. Brain Res, 1995, 674(1): 133–136CrossRefGoogle Scholar
  13. 13.
    Avdulov N A, Chochina S V, Igbavboa U, et al. Amyloid beta-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J Neurochem, 1997, 68(5): 2086–2091CrossRefGoogle Scholar
  14. 14.
    Zubenko G S. Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology, 1992, 6(2): 77–93Google Scholar
  15. 15.
    Hajimohammadreza I, Brammer M J, Eagger S, et al. Platelet and erythrocyte membrane changes in Alzheimer’s disease. Biochim Biophys Acta, 1990, 1025(2): 208–214CrossRefGoogle Scholar
  16. 16.
    van Hoeven RP, van Blitterswijk W J, Emmelot P. Fluorescence polarization measurements on normal and tumour cells and their corresponding plasma membrance. Biochim Biophys Acta, 1979, 552(1): 44–54Google Scholar
  17. 17.
    Arispe N, Pollard H B, Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1–40)] in bilayer membranes. Proc Natl Acad Sci USA, 1993, 90(22): 10573–10577CrossRefGoogle Scholar
  18. 18.
    Simakova O, Arispe N J. Early and late cytotoxic effects of external application of the Alzheimer’s Abeta result from the initial formation and function of Abeta ion channels. Biochemistry, 2006, 45(18): 5907–5915CrossRefGoogle Scholar
  19. 19.
    Quist A, Doudevski I, Lin H, et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA, 2005, 102(30): 10427–10432CrossRefGoogle Scholar
  20. 20.
    Arispe N, Diaz J C, Simakova O. Aβ ion channels. Prospects for treating Alzheimer’s disease with Aβ channel blockers. Biochimica et Biophysica Acta, 2007, 1768: 1952–1965CrossRefGoogle Scholar
  21. 21.
    Roth G S, Joseph J A, Mason R P. Membrane alterations as causes of impaired signal transduction in Alzheimer’s disease and aging. Trends Neurosci, 1995, 18(5): 203–206CrossRefGoogle Scholar
  22. 22.
    Lin H, Bhatia R, Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer’s disease pathophysiology. Faseb J, 2001, 15(13): 2433–2444CrossRefGoogle Scholar
  23. 23.
    Rhee S K, Quist A P, Lal R. Amyloid beta protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel. J Biol Chem, 1998, 273(22): 13379–13382CrossRefGoogle Scholar
  24. 24.
    Lin H, Zhu Y J, Lal R. Amyloid beta protein (1–40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry, 1999, 38(34): 11189–11196CrossRefGoogle Scholar

Copyright information

© Science in China Press and Springer-Verlag GmbH 2009

Authors and Affiliations

  • Ying Niu
    • 1
  • BaiYang Sheng
    • 1
  • Bo Song
    • 1
  • LingLing Liu
    • 1
  • XiuFang Zhang
    • 1
  • NanMing Zhao
    • 2
  • YanDao Gong
    • 1
  1. 1.State Key Laboratory of Biomembrane and Membrane Biotechnology, Department of Biological Sciences and BiotechnologyTsinghua UniversityBeijingChina
  2. 2.Medical SchoolTsinghua UniversityBeijingChina

Personalised recommendations